Ixiaro (Japanese encephalitis vaccine (inactivated, adsorbed))
- Region
- 🇪🇺 EU
- Active substance
- Japanese encephalitis vaccine (inactivated, adsorbed)
- Company
- Valneva Austria GmbH
- Status
- Authorised
- Therapeutic area
- Encephalitis, Japanese; Immunization
- EU approval
- Tue 31 Mar 2009
- Application
- EMEA/H/C/000963
- ATC
- J07BA02
- Official record
- www.ema.europa.eu
Indication
Ixiaro is indicated for active immunisation against Japanese encephalitis in adults, adolescents, children and infants aged two months and older. Ixiaro should be considered for use in individuals at risk of exposure through travel or in the course of their occupation.
Regulatory milestones
No milestones recorded in the last year.
Follow Ixiaro
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.